Increased of exhaled breath condensate neutrophil chemotaxis in acute exacerbation of COPD

Respiratory Research

Table 1 Demographic, functional and therapeutic characteristics

	Healthy controls	Stable COPD patients	Exacerbated COPD patients
	Healthy controls	Stable COPD patients	Outpatients	Hospitalized
No of subjects	20	17	16	17
Age (yrs)	57.1 ± 8.7	59.8 ± 7.4	61.8 ± 6.4	63.8 ± 8.4
Male/female number	8/3	13/4	13/3	13/4
BMI (kg/m²)	24.2 ± 3.3	25.8 ± 3.4	26.1 ± 4.8	26.7 ± 7.1
Number of pack years	25.2 ± 13.8	41.3 ± 18.9 †	41.4 ± 11.8 †	43.3 ± 14.3 ††
FEV1,% predicted value	99.6 ± 14.8	52.5 ± 18.0 †††	48.1 ± 11.6 †††	37.0 ± 14.1 †††*
FEV1/FVC%	77.5 ± 4.7	50.7 ± 11.7 †††	47.0 ± 13.3 †††	46.2 ± 9.5 †††
GOLD stages No
GOLD 2		11	10	4*#
GOLD 3-4		6	6	13*#
Inhaled corticosteroid
Number		13	15	14
Mean daily dose of ICSμg^¶		1235.3 ± 877.1	1421.9 ± 553.2	1588.2 ± 678.6
Long-acting B2 agonist, number		13	15	14
Long-acting Anticholinergic, number		15	14	16
Oral steroids^¶¶, number		0	0	17

Data are expressed as means ± SD.
^¶Expressed as beclomethasone equivalent (In converting corticosteroid drugs to a beclomethasone equivalent, we assumed that 1 mg of beclomethasone was equivalent to 0.8 mg of budesonide, 0.5 mg of fluticasone).
^¶¶Taken at the moment of sampling.
p < 0.05, †† p <0.01, ††† p < 0.001 vs controls. *p < 0.05 vs stable COPD, #p < 0.05 vs outpatients with exacerbation of COPD.
COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV₁: forced expiratory volume in one second; FVC: forced vital capacity.

ISSN: 1465-993X